You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,274,111


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,274,111
Title:Method for the diagnosis of and/or monitoring mucormycosis
Abstract: A method is described for the diagnosis and/or monitoring of active or previous infection by Mucor which consists in the identification of Mucorales-specific T cells in samples from biological fluids taken from the patient and put into contact with a Mucor antigen. These specific immune responses can be detected by the execution of immunoenzymatic assays (ELISPOT, Quantiferon) or of immunocytofluorimetric assays [Cytokine Secretion Assay (CSA), Intracellular Cytokine Staining (ICS)] in vitro. In greater detail, the method in question provides for checking for the presence of specific IFN-.gamma. producing T cells, of specific IL-10 producing T cells and/or specific IL-4 producing T cells.
Inventor(s): Luppi; Mario (Nonantola, IT), Barozzi; Patrizia (Modena, IT), Potenza; Leonardo (Modena, IT), Vallerini; Daniela (Carpi, IT), Fabio; Forghieri (Formigine, IT)
Assignee: Universita\' Degli Studi Di Modena E Reggio Emilia (Modena, IT)
Application Number:13/990,784
Patent Claims:1. A method of diagnosing and/or monitoring invasive Mucormycosis in a patient having said Mucormycosis due to a fungal pathogen of the order Mucorales, the method comprising performing an in vitro assay, wherein a biological fluid obtained from the patient is contacted with an antigen extractable from conidia and/or hyphae of the fungal pathogen of the order Mucorales and determining the number of specific IFN-producing T cells, specific IL-10-producing T cells, and specific IL-4-producing T cells, wherein the T cells are specific to the antigen.

2. The method of claim 1, wherein the in vitro assay is an immunoenzymatic assay.

3. The method of claim 2, wherein the immunoenzymatic assay is an ELISPOT assay.

4. The method of claim 2, wherein the immunoenzymatic assay is a Quantiferon assay.

5. The method of claim 1, wherein the assay is an immunocytofluorometric assay.

6. The method of claim 5, wherein the immunocytofluorometric assay is cytokine secretion assay (CSA) or intracellular cytokine staining (ICS) assay.

7. The method of claim 1, wherein the biological fluid is blood, bronchioalveolar lavage liquid and/or pleural fluid.

8. The method of claim 1, wherein the antigen is a proteinaceous extract.

9. The method of claim 1, wherein the positivity threshold number for the specific IFN-producing T cells, specific IL-10-producing T cells, and specific IL-4-producing T cells is between 2 to 10 spot forming cells (SFCs).

10. The method of claim 1, wherein the method comprises the following steps: (a) culture of the fungal pathogen of the order Mucorales in Saboraud's culture medium for 2-4 days; (b) subsequent collection of the conidia by washing of the surface layer of the fungal culture with sterile water; (c) subsequent filtration and centrifugation of the washed conidia to obtain the conidia pellet; (d) subsequent suspension of the conidia pellet in liquid Saboraud culture medium and stirring for about 12 hours to achieve germination of the conidia; (e) subsequent washing of the germinated conidia in a saline solution; (f) subsequent deactivation of the germinated conidia by heat at 100.degree. C. for 1 hour; (g) subsequent sonication of the heat-deactivated germinated conidia and (h) subsequent resuspension of the sonicated conidia from step (g) in a saline solution or in a fungal culture medium; and (i) subsequent optional freezing.

11. The method of claim 1, wherein the method comprises the following steps: (j) culture of the fungal pathogen of the order Mucorales in Saboraud's agar culture plates; (k) subsequent collection of the hyphae followed by suspension of the hyphae in sterile water; (l) subsequent filtration and centrifugation of the hyphae suspended in sterile water to obtain the hyphae mycete pellet; (m) subsequent freezing and thawing of the mycete pellet; (n) subsequent homogenization of the mycete pellet in the presence of equal volume of beads made of inert material or glass equal to the volume of the mycete and (o) subsequent centrifugation with subsequent optional freezing.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.